Nothing Special   »   [go: up one dir, main page]

ECSP045297A - Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn? - Google Patents

Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn?

Info

Publication number
ECSP045297A
ECSP045297A EC2004005297A ECSP045297A ECSP045297A EC SP045297 A ECSP045297 A EC SP045297A EC 2004005297 A EC2004005297 A EC 2004005297A EC SP045297 A ECSP045297 A EC SP045297A EC SP045297 A ECSP045297 A EC SP045297A
Authority
EC
Ecuador
Prior art keywords
inhibitors
microgly
interleucine
ifn
interrupt
Prior art date
Application number
EC2004005297A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045297A publication Critical patent/ECSP045297A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere al uso de inhibidores de la microglía para preparar fármacos que inhiben las reacciones inmunes asociadas con monocitos, macrófagos y células-T y a su uso para el tratamiento de enfermedades inmunológicas asociadas con células-T y reacciones inflamatorias no asociadas con células-T.
EC2004005297A 2002-02-15 2004-09-14 Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn? ECSP045297A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10207843A DE10207843A1 (de) 2002-02-15 2002-02-15 Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen

Publications (1)

Publication Number Publication Date
ECSP045297A true ECSP045297A (es) 2004-10-26

Family

ID=27674912

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005297A ECSP045297A (es) 2002-02-15 2004-09-14 Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn?

Country Status (21)

Country Link
EP (1) EP1474138A1 (es)
JP (1) JP2005522447A (es)
KR (1) KR20040084909A (es)
CN (1) CN1756546A (es)
AR (1) AR039556A1 (es)
AU (1) AU2003245523A1 (es)
BR (1) BR0307706A (es)
CA (1) CA2475770A1 (es)
DE (1) DE10207843A1 (es)
EC (1) ECSP045297A (es)
MX (1) MXPA04007943A (es)
NO (1) NO20043840L (es)
PE (1) PE20030906A1 (es)
PL (1) PL371327A1 (es)
RS (1) RS71304A (es)
RU (1) RU2004127677A (es)
TW (1) TW200306823A (es)
UA (1) UA81111C2 (es)
UY (1) UY27662A1 (es)
WO (1) WO2003068225A1 (es)
ZA (1) ZA200407382B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10207844A1 (de) * 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
CA2601557A1 (en) * 2005-03-17 2006-09-21 Proyteco De Biomedicina Cima, S.L. Use of 5'-methylthioadenosine (mta) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection
EP2858983B1 (en) * 2012-06-11 2018-04-18 UCB Biopharma SPRL Tnf-alpha modulating benzimidazoles
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
WO2017079519A1 (en) 2015-11-06 2017-05-11 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
EP3741747B1 (en) * 2015-12-15 2024-10-16 The Board of Trustees of the Leland Stanford Junior University Method for preventing and/or treating anxiety
US20170190689A1 (en) 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
CN118063470A (zh) 2017-10-18 2024-05-24 因赛特公司 作为PI3K-γ抑制剂的由叔羟基取代的缩合咪唑衍生物
HRP20240252T1 (hr) 2018-09-05 2024-05-24 Incyte Corporation Kristalni oblici inhibitora fosfoinozitid 3 kinaze (pi3k)
PL3860998T3 (pl) 2018-10-05 2024-06-17 Annapurna Bio Inc. Związki i kompozycje do leczenia schorzeń związanych z aktywnością receptora apj
CN112341450B (zh) * 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341451B (zh) * 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4330959A1 (de) * 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
BR0107628A (pt) * 2000-01-14 2002-10-08 Schering Ag l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10135050A1 (de) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
RS71304A (en) 2006-10-27
EP1474138A1 (de) 2004-11-10
RU2004127677A (ru) 2005-06-10
ZA200407382B (en) 2005-09-14
AR039556A1 (es) 2005-02-23
KR20040084909A (ko) 2004-10-06
WO2003068225A1 (de) 2003-08-21
MXPA04007943A (es) 2004-11-26
CA2475770A1 (en) 2003-08-21
TW200306823A (en) 2003-12-01
PL371327A1 (en) 2005-06-13
JP2005522447A (ja) 2005-07-28
UA81111C2 (en) 2007-12-10
NO20043840L (no) 2004-11-12
PE20030906A1 (es) 2004-01-17
DE10207843A1 (de) 2003-09-04
AU2003245523A1 (en) 2003-09-04
CN1756546A (zh) 2006-04-05
UY27662A1 (es) 2003-09-30
BR0307706A (pt) 2005-01-11

Similar Documents

Publication Publication Date Title
ECSP045297A (es) Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn?
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
CR7875A (es) Variantes de inmunoglobina y usos de esto
ES2148525T3 (es) Inmunomoduladores.
UY27720A1 (es) Aroilpiridinonas monocíclicas,
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
UY26370A1 (es) "imidazo-5-il-aminas bicíclicas, medicamentos que las contienen, su uso para la preparación de medicamentos y procedimiento para su preparación".
ES2192839T3 (es) Timosina beta 4 oxidada.
PA8587801A1 (es) Isomeros posicionales de interferon alfa 2-a monopegilado
MX2007007259A (es) Inhibidores de homodimerizacion de myd88.
CL2003002678A1 (es) Compuestos derivados de piperidina, moduladores de la actividad del receptor ccr5; procedimiento de preparacion; composicion farmaceutica, y su uso en el tratamiento de enfermedades inmunologicas, inflamatorias, asma, artritis reumatoidea y ateroescl
HRP20050439B1 (en) New use of dextran sulfate
DE60041655D1 (de) Auslösender rezeptor der an der natürlichen cytotoxizität der menschlichen natürlichen killerzellen (natural killer cells) beteiligt ist und antikörper die diesen rezeptor identifizieren
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
UY27312A1 (es) Nuevos heterociclos 3
PT1017667E (pt) 2-amino-6-metil-7-acetil-tetralina e composicoes farmaceuticas para a prevencao e para o tratamento terapeutico de patologias inflamatorias e/ou de natureza autoimunitaria
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
CR7441A (es) Inhibidores de la microglia para interrumpir reacciones inmunes asociadas con interleucina 12 y ifny
PA8579401A1 (es) Derivados de 2,3-dihidro-isoindol-1-ona como inhibidores de mao-b
UY26945A1 (es) Alcanosulfonatos de fenoxifenilo
ECSP045296A (es) Derivados de benzimidazol 1-fenil-2-heteroaril-sustituidos, su uso para preparar medicamentos para el tratamiento de enfermedades inmunológicas
DK1107779T3 (da) Lægemidler til minipulation af T-celle immunreaktion
ES2188538T3 (es) Uso de 15-desoxipergualina para el tratamiento de enfermedades inflamatorias hiperreactivas y enfermedades autoinmunes.
MD2053C2 (ro) Remediu cu acţiune interferonogenă